Cost of routine immunization of young children against rotavirus infection with Rotarix versus RotaTeq

Vaccine

Volumn 27, Issue 36, 2009, Pages 4930-4937

  Weycker, Derek ^a   Sofrygin, Oleg ^a   Kemner, Jason E ^b   Pelton, Stephen I ^c   Oster, Gerry ^a  

^a POLICY ANALYSIS INC PAI   (United States)

^b GLAXOSMITHKLINE   (United States)

^c BOSTON MEDICAL CENTER   (United States)

Author keywords

Diarrhea; Gastroenteritis; Rotavirus; Rotavirus vaccine

Indexed keywords

ROTAVIRUS VACCINE;

ARTICLE; CHILD; COHORT ANALYSIS; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; COST OF ILLNESS; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; HEALTH CARE COST; HUMAN; IMMUNIZATION; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; UNITED STATES; VIRAL GASTROENTERITIS;

CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; FEMALE; GASTROENTERITIS; HUMANS; IMMUNIZATION; INFANT; INFANT, NEWBORN; MALE; MODELS, STATISTICAL; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; UNITED STATES; VACCINES, ATTENUATED;

EID: 67650602058     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.06.025     Document Type: Article

References (42)

1. MMWR Recommendations and Reports. Prevention of Rotavirus Gastroenteritis among Infants and Children. Recommendations of the Advisory Committee on Immunization Practices (ACIP) 2006; 55(August (RR12)):1-13.
2. Vesikari T., Matson D.O., Dennehy P., Van Damme P., Santosham M., Rodriguez Z., et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 354 (2006) 23-33
3. Widdowson M.C., Meltzer M.I., Zhang X., Bresee J.S., Parashar U.D., and Glass R.I. Cost-effectiveness and potential impact of rotavirus vaccination in the United States. Pediatrics 119 (2007) 684-697
4. Vesikari T., Karvonen A., Prymula R., Schuster V., Tejedor J.C., Cohen R., et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 370 (2007) 1757-1763
5. Jit M., and Edmunds W.J. Evaluating rotavirus vaccination in England and Wales. Part II. The potential cost-effectiveness of vaccination. Vaccine 25 (2007) 3971-3979
6. Newall A.T., Beutels P., Macartney K., Wood J., and MacIntyre C.R. The cost-effectiveness of rotavirus vaccination in Australia. Vaccine 25 (2007) 8851-8860
7. Tucker A.W., Haddix A.C., Bresee J.S., Holman R.C., Parashar U.D., and Glass R.I. Cost-effectiveness analysis of a rotavirus immunization program for the United States. JAMA 279 (1998) 1371-1376
8. Rodriguez W.J., Kim H.W., Brandt C.D., Schwartz R.H., Gardner M.K., Jeffries B., et al. Longitudinal study of rotavirus infection and gastroenteritis in families served by a pediatric medical practice: clinical and epidemiologic observations. Pediatr Infect Dis J 6 (1987) 170-176
9. Gurwith M., Wenman W., Hinde D., Feltham S., and Greenberg H. A prospective study of rotavirus infection in infants and young children. J Infect Dis 144 (1981) 218-224
10. Parashar U.D., Holman R.C., Clarke M.J., Bresee J.S., and Glass R.I. Hospitalizations associated with rotavirus diarrhea in the United States, 1993 through 1995: surveillance based on the new ICD-9-CM rotavirus-specific diagnostic code. J Infect Dis 177 (1997) 13-17
11. National Center of Health Statistics. US National Immunization Survey: Public-Use Files 2003. Hyattsville, MD: National Center for Health Statistics, Centers for Disease Control and Prevention, available at: www.cdc.gov/nis/datafiles.htm; 2003 [accessed April 7, 2008].
12. US Census Bureau. Population projections, available at: www.census.gov [accessed June 22, 2008].
13. Brandt C.D., Kim H.W., Rodriguez W.J., Arrobio J.O., Jeffries B.C., Stallings E.P., et al. Pediatric viral gastroenteritis during eight years of study. J Clin Microbiol 18 (1983) 71-78
14. Waters V., Ford-Jones E.L., Petric M., Fearon M., Corey P., and Moineddein R. Etiology of community-acquired pediatric viral diarrhea: a prospective longitudinal study in hospitals, emergency departments, pediatric practices and child care centers during the winter rotavirus outbreak, 1997-1998. Pediatr Infect Dis J 19 (2000) 843-848
15. De Wit M.A., Koopmans M.P., Kortbeek L.M., van Leeuwen N.J., Bartelds A.I., and van Duynhoven Y.T. Gastroenteritis in sentinel general practices, the Netherlands. Emerg Infect Dis 7 (2001) 82-91
16. Caeiro J.P., Mathewson J.J., Smith M.A., Jiang Z.D., Kaplan M.A., and Dupont H.L. Etiology of outpatient pediatric nondysenteric diarrhea: a multicenter study in the United States. Pediatr Infec Dis J 18 (1999) 94-97
17. Kotloff K.L., Wasserman S.S., Steciak J.Y., Tall B.D., Losonsky G.A., Prasanna Nair, et al. Acute diarrhea in Baltimore children attending an outpatient clinic. Pediatr Infect Dis J 7 (1988) 753-759
18. Koopman J.S., Turkish V.J., Monto A.S., Gouvea V., Srivastava S., and Isaacson R.E. Patterns and etiology of diarrhea in three clinical settings. Am J Epidemiol 119 (1984) 114-123
19. Denno D.M., Stapp J.R., Boster D.R., Qin X., Clausen C.R., Del Beccaro K.H., et al. Etiology of diarrhea in pediatric outpatient settings. Pediatr Infect Dis J 24 (2005) 142-148
20. Kilgore P.E., Holman R.C., Clarke M.J., and Glass R.I. Trends of diarrheal disease-associated mortality in U.S. children, 1968 through 1991. JAMA 274 (1995) 1143-1148
21. Glass R.I., Kilgore P.E., Holman R.C., Jin S., Smith J.C., Woods P.A., et al. The epidemiology of rotavirus diarrhea in the United States: surveillance and estimates of disease burden. J Infect Dis 174 Suppl. 1 (1996) S5-S11
22. Bureau of Labor Statistics. Medical care component of consumer price index: all urban consumers, available at http://stats.bls.gov/cpi/home.htm [accessed April 7, 2008].
23. Avendano P., Matson D.O., Long J., Whitney S., Matson C.C., and Pickering L.K. Costs associated with office visits for diarrhea in infants and toddlers. Pediatr Infect Dis J 12 (1993) 897-902
24. Grosse S.D. Productivity loss tables. In: Haddix A.C., Teutsch S.M., and Corso P.S. (Eds). Prevention Effectiveness (2003), Oxford University Press, New York, NY 245-257
25. Ferson M.J., Stringfellow S., McPhie K., McIver C.J., and Simos A. Longitudinal study of rotavirus infection in child-care centres. J Paediatr Child Health 33 (1997) 157-160
26. Coffin S.E., Elser J., Marchant C., Sawyer M., Pollara B., Fayorsey R., et al. Impact of acute rotavirus gastroenteritis on pediatric outpatient practices in the United States. Pediatr Infect Dis J 25 (2006) 584-589
27. Hardy A.M., Lairson D.R., and Morrow A.L. Costs associated with gastrointestinal-tract illness among children attending daycare centers in Houston, Texas. Pediatrics 94 (1994) 1091-1093
28. US Bureau of Labor Statistics. Employer costs for employee compensation, available at: www.bls.gov/ecthome.htm [accessed June 22, 2008].
29. First Databank, available at: www.firstdatabank.com; June, 2008 [accessed on June 22, 2008].
30. RBRVS. Salt Lake City, UT: Ingenix Inc. 2008.
31. Centers for Disease Control and Prevention. Proposed recommendations from the ACIP rotavirus vaccines working group, available at: www.cdc.gov/vaccines/recs/ACIP/downloads/mtg-slides-feb08/26-2-rotavirus .pdf [accessed August 8, 2008].
32. Centers for Disease Control and Prevention. Statistics and Surveillance, available at: www.cdc.gov/vaccines/stats-surv [accessed July 24, 2008].
33. Briggs A., Sculpher M., Dawson J., Fitzpatrick R., Murray D., and Malchau H. The use of probabilistic decision models in technology assessment: the case of total hip replacement. Appl Health Econ Health Policy 3 (2004) 79-89
34. Weinstein M.C., Siegel J.E., Gold M.R., Kamlet M.S., and Russell L.B. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 276 (1996) 1253-1258
35. Lorgelly P.K., Joshi D., Iturriza Gómara M., Gray J., and Mugford M. Exploring the cost effectiveness of an immunization programme for rotavirus gastroenteritis in the United Kingdom. Epidemiol Infect 163 (2008) 44-55
36. Goossens L.M.A., Standaert B., Hartwig N., Hovels A.M., and Maiwenn J.A. The cost-utility of rotavirus vaccination with Rotarix (RIX4414) in the Netherlands. Vaccine 26 (2008) 1118-1127
37. Griffin D.D., Kirkwood C.D., Parashar U.D., Woods P.A., Bresee J.S., Glass R.I., et al. Surveillance of rotavirus strains in the United States: identification of unusual strains. J Clin Microbiol 38 (2000) 2784-2787
38. American Academy of Pediatrics. Prevention of rotavirus disease: guidelines for use of rotavirus vaccine. Pediatrics 119 (2007) 171-182
39. Vesikari R, Matson D, Dennehy P, Dallas M, Itzler R, Dinubile M, et al. Efficacy of the pentavalent rotavirus vaccine in subjects after 1 or 2 doses in the rotavirus efficacy and safety trial (REST). Infectious Disease Society of America 2006; Abstract 145.
40. Bernstein D. Efficacy of the pentavalent rotavirus vaccine in subjects after 1 or 2 doses in the rotavirus efficacy and safety trial (Letter to Editor). Pediatrics 121 (2008) 223
41. Clements-Mann M., Makhene M.K., Mrukowicz J., Wright P.F., Hoshino Y., Midthun K., et al. Safety and immunogenicity of live attenuated quadrivalent human-bovine (UK) reassortant rotavirus vaccine administered with childhood vaccines to infants. Vaccine 19 (2001) 4676-4684
42. Dennehy P.H., and North American Human Rotavirus Vaccine Study Group. A short-report on the highlights of world-wide development of RIX4414: a North-American experience: comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine (RIX4414) in infants in the United States and Canada. Vaccine 24 (2006) 3780-3781